Takeda Canada, Inc. has reacquired Canadian commercial rights to Actos, an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda licensed the drug to Lilly in 1999 as part of a worldwide agreement. “Reacquiring the commercial rights to Actos is Takeda’s first opportunity to establish a commercial presence in Canada,” said Daaron Dohler, general manager at Takeda Canada. “It also underscores Takeda’s ongoing efforts to reinforce our global operatio...